Table 1.
IC50 values [a] (µg/mL) of compounds.
| Compounds | IC50 (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| 8a | 8b | 8c | 8d | 8e | 8f | 8g | 8h | |
| HCT116 [b] | 17.80 ± 0.03 | 21.01 ± 0.38 | 30.12 ± 0.02 | 27.75 ± 0.11 | 35.03 ± 0.25 | 98.43 ± 0.13 | 86.49 ± 0.02 | 100.38 ± 0.04 |
| MCF-7 [c] | 33.34 ± 0.28 | 30.81 ± 0.05 | 28.26 ± 0.13 | 26.87 ± 0.06 | 31.31 ± 0.13 | 342.19 ± 0.22 | 275.52 ± 0.07 | 546.68 ± 0.31 |
| EC9708 [d] | 44.00 ± 0.61 | 38.94 ± 0.02 | 30.24 ± 0.23 | 41.47 ± 0.14 | 47.35 ± 0.21 | 257.31 ± 0.20 | 300.18 ± 0.11 | 112.41 ± 0.03 |
| QBC939 [e] | 43.13 ± 0.05 | 72.88 ± 0.16 | 34.25 ± 0.42 | 36.71 ± 0.04 | 37.73 ± 0.23 | 357.52 ± 0.08 | 290.94 ± 0.05 | 112.02 ± 0.03 |
| SGC-7901 [f] | 55.82 ± 0.16 | 67.98 ± 0.18 | 61.60 ± 0.14 | 60.83 ± 0.12 | 72.31 ± 0.33 | 165.34 ± 0.21 | 235.81 ± 0.02 | 200.35 ± 0.05 |
| HeLa [g] | 29.75 ± 0.15 | 27.87 ± 0.22 | 25.94 ± 0.22 | 28.70 ± 0.17 | 48.82 ± 0.13 | 241.31 ± 0.13 | 122.52 ± 0.05 | 334.28 ± 0.04 |
| SW480 [h] | 31.09 ± 0.10 | 42.36 ± 0.68 | 39.50 ± 0.31 | 43.08 ± 0.05 | 60.49 ± 0.07 | 155.38 ± 0.14 | 158.37 ± 0.04 | 119.93 ± 0.03 |
| HepG2 [i] | 44.65 ± 0.03 | 43.96 ± 0.53 | 58.34 ± 0.22 | 40.11 ± 0.02 | 49.07 ± 0.08 | 296.42 ± 0.21 | 520.52 ± 0.22 | 467.74 ± 0.06 |
| HL-7702 [j] | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 |
| FHC [k] | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 | >1000 |
[a] The half-maximal inhibitory concentration (IC50) of cells treated with the compounds 48 h. [b,h] Colon cancer, [c] Breast cancer, [d] Esophageal cancer, [e] Cholangiocarcinoma, [f] Gastric cancer, [g] Cervical cancer, [i] Liver cancer, [j] Normal human hepatocyte, [k] Normal human colorectal mucosa.